Skip to main content

View full-text article in PMC

. 2007 Jun 27;45(11):3713–3720. doi: 10.1128/JCM.02012-06

TABLE 3.

Results of in vitro antifungal susceptibility testing^a

Organism or type	MIC (mg/liter)
	Amphotericin B		Itraconazole		Voriconazole		Posaconazole
	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀	MIC₅₀	MIC₉₀
E. phaeomuriformis	0.5	1	≤0.015	0.03	0.03	0.06	≤0.015	≤0.015
E. xenobiotica	0.25	0.5	0.03	0.125	0.125	0.5	≤0.015	0.03
E. bergeri	0.25	0.25	0.125	0.25	1.0	1.0	0.03	0.03
E. lecanii-corni	0.25	0.5	0.06	0.125	0.06	0.5	≤0.015	0.03
E. spinifera	0.5	0.5	0.03	0.06	0.125	0.5	≤0.015	0.03
E. jeanselmei	0.5	1	0.03	0.06	0.125	0.25	≤0.015	0.03
E. mesophila	0.25	0.5	0.125	0.25	0.5	0.25	0.06	0.06
E. dermatitidis	0.5	1.0	0.125	0.25	0.125	0.25	0.03	0.06
E. oligosperma	0.25	0.5	0.06	0.125	0.25	1.0	0.03	0.03
Susceptible^b	≤1.0		≤0.5		≤2.0		?
Resistant^c	>2.0		≥1.0		>2.0		?

^a

No defined breakpoints are available for the genus Exophiala, and the clinical correlates are primarily anecdotal. AMB, amphotericin B, ITRA.

^b

Suggested MIC for clinical efficacy based upon in vitro data.

^c

Suggested MIC for less than favorable clinical outcome based upon in vitro data.